Company Overview
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Why Investors Should Care
Revenue has grown at a 32.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.36.
Recent Developments
- Dec 2025 Revenue of $3.85M (-30.9% YoY); net profit $-8.48M.
- Trailing 12 Months Year-on-year growth — revenue -60.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 32.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 32.01% |
| 1 Year: | -60.70% |
Stock Price Performance
| 1 Year: | -61.83% |
| 6 Months: | -33.21% |
| 3 Months: | -12.48% |
| 1 Month: | -15.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.47 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 32.0% over 5 years.
CONS
- Trading 65.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EVGN Evogene Ltd. PHARMA | 0.51 | -0.29 | $8.06M | 0.00% | - | - | 32.01% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.61M | 2.44M | 884.00K | 312.00K | 314.00K |
| Cost of Revenue | 755.00K | 1.61M | 136.00K | 157.00K | 2.28M |
| Gross Profit | 856.00K | 830.00K | 748.00K | 155.00K | -1.97M |
| Operating Expenses | 5.42M | 4.96M | 3.82M | 2.88M | 3.24M |
| Operating Income | -4.57M | -4.13M | -3.07M | -2.72M | -5.21M |
| EBITDA | -2.54M | -1.95M | -2.61M | -1.99M | -6.46M |
| Interest Expense | -3.13M | 464.00K | 628.00K | 453.00K | -1.38M |
| Pretax Income | 2.00K | -2.99M | -3.53M | -2.73M | -5.34M |
| Tax Provision | 7.00K | 0 | 1.00K | 1.00K | 0 |
| Net Income | 427.00K | -2.59M | -4.46M | 3.87M | -5.31M |
| Diluted EPS | 0.06 | -0.38 | -0.62 | 0.44 | -0.61 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.68M | 2.98M | 5.58M | 3.85M |
| Cost of Revenue | 909.00K | 1.49M | 2.38M | 4.09M |
| Gross Profit | 766.00K | 1.49M | 3.20M | -241.00K |
| Operating Expenses | 27.71M | 23.70M | 21.95M | 13.79M |
| Operating Income | -26.94M | -22.20M | -18.76M | -14.03M |
| EBITDA | -27.01M | -20.53M | -13.36M | -12.20M |
| Interest Expense | 165.00K | 114.00K | 63.00K | 157.00K |
| Pretax Income | -29.75M | -21.95M | -14.81M | -13.50M |
| Tax Provision | 90.00K | 19.00K | 9.00K | 1.00K |
| Net Income | -26.64M | -23.88M | -16.48M | -8.48M |
| Diluted EPS | -6.50 | -5.20 | -2.89 | -1.08 |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -23.68M | -21.58M | -19.70M | -13.50M |
| Investing Cash Flow | - | 13.27M | -4.54M | 9.62M | 17.74M |
| Financing Cash Flow | - | 9.34M | 18.15M | 4.66M | -6.60M |
| Capital Expenditure | - | -1.17M | -577.00K | -626.00K | -135.00K |
| Free Cash Flow | - | -24.85M | -22.15M | -20.33M | -13.64M |
| Net Change in Cash | - | -1.06M | -7.96M | -5.42M | -2.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 45.7% | 50.0% | 57.3% | -6.3% |
| Operating Margin % | -1,608.4% | -744.6% | -336.3% | -364.2% |
| Net Margin % | -1,590.3% | -800.8% | -295.6% | -220.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SilverArc Capital Management, LLC | 0.61% | 308.55K | $153.97K |
| 2 | Morgan Stanley | 0.06% | 28.40K | $14.17K |
| 3 | BNP Paribas Financial Markets | 0.02% | 9.14K | $4.56K |
| 4 | LPL Financial LLC | 0.01% | 6.68K | $3.33K |
| 5 | JP Morgan Chase & Company | 0.01% | 3.94K | $1.97K |
| 6 | UBS Group AG | 0.01% | 6.25K | $3.12K |
| 7 | Geode Capital Management, LLC | 0.01% | 5.90K | $2.94K |
| 8 | Renaissance Technologies, LLC | 0.01% | 4.48K | $2.23K |
| 9 | Citadel Advisors Llc | 0.01% | 5.99K | $2.99K |
| 10 | PNC Financial Services Group, Inc. | 0.01% | 3.80K | $1.90K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EVGN
Evogene (EVGN) sets seven-member board after 2026 shareholder vote - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxONU9BLTdlaExFOHc5QXhwZzl3ODRiQXVJRnFCWjZ0b1hYdFZFclhyN1dmM2NLRENuZm92eWNVcG1OZHF1c0IzRUhwOHBaS0h5MENLN2o3ZTFiVGZWVU4xN0VQcVNtSTJsRTBnVUpzZGttZlBDbU5PXzBub1ZOZlVIQzQ0YjI0MVJiQWVTSm…
EVOGENE ($EVGN) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMif0FVX3lxTFBxNVlERU5LbThSMUFiUUNyTWlucjZjaUtnV0NIMXdWem5mRmFRODhCaUhQUEhUWVZ2UU5iWnpHOXJBZlRGS0IybktmUDdFalE0Y3JoUGwwcVNrLTltRHFsMlZkX2J2VEhKOTJ1SWxlV3VkN052b19CRmg0RHh5Ulk?oc=5" target="_bla…
EVGN Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE16Yno0cFAxRTVZSDc2N2xOeTJtNzJKRXBSQnlxa24tWGlmNm45TVpSLVhWQUJCVGY1X2V2TkktT1NiSTlxOE1UdUp4VWExc0QyU3YwVDBjSjNxM1diZG53d2NkaWFBYnhCTU1TS3ozRDBjdHdXRE5DTTRn?oc=5" target="_blank">EVG…
Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News, EVGN Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE13b0xVcjllOThOWmEwdHRQc2dGSEJYdzAwUmlDNVV6SXUyalM0RGN3WmpIY1hBR3NXTEJZWXd6d05YRk50ZWQ2amlvUTBGamhTZ01ieEV3?oc=5" target="_blank">Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News…
Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQWWZmTDM2N0duMWNXTko0TE5CMnZMSXV3NmJfVXNPRHkwYTg3M3ZQNk1HWFJHcWJBM3JVcllwdzN2aWlOMVoyMzYtTV9EVjhYN2dtc0tUSDZaS01YRlFTeTNHZzBTODREbXFDbmdQRGFBT1U5SDc5bER5Skl2QU1CMmszSEtrNmtfZzdORU…
EVGN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9iM2hFYTZVN1ZkcG5pUmR4U0ItS1lCcWpDZGdYekNtTXBJdlBucVAzUFNyU01UbFRDOS1weWRGSldqUF9LVHc?oc=5" target="_blank">EVGN</a> <font color="#6f6f6f">Finviz</font>…
EVGN — Frequently Asked Questions
What is the current share price of Evogene Ltd. (EVGN)?
As of 2026-09-19 21:16 PDT, Evogene Ltd. (EVGN) trades at $0.51 on NasdaqCM. Its 52-week range is $0.39 to $1.46.
What is the market capitalisation of EVGN?
Evogene Ltd. (EVGN) has a market capitalisation of $8.06M on NasdaqCM.
What is the P/E ratio of EVGN?
EVGN trades at a trailing price-to-earnings (P/E) ratio of -0.29. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -2.07.
Is EVGN a good stock to buy?
This page provides a data-driven analysis of Evogene Ltd. (EVGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.